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ABSTRACT
Introduction Idiopathic pulmonary fibrosis (IPF) is 
a fatal disease of lung scarring. Many patients later 
develop raised pulmonary vascular pressures, sometimes 
disproportionate to the interstitial disease. Previous 
therapeutic approaches that have targeted pulmonary 
vascular changes have not demonstrated clinical efficacy, 
and quantitative assessment of regional pulmonary 
vascular involvement using perfusion imaging may 
provide a biomarker for further therapeutic insights.
Methods We studied 23 participants with IPF, using 
dynamic contrast- enhanced MRI (DCE- MRI) and 
pulmonary function tests, including forced vital capacity 
(FVC), transfer factor (TL
CO
) and coefficient (K
CO
) of the 
lungs for carbon monoxide. DCE- MRI parametric maps 
were generated including the full width at half maximum 
(FWHM) of the bolus transit time through the lungs. Key 
metrics used were mean (FWHM
mean
) and heterogeneity 
(FWHM
IQR
). Nineteen participants returned at 6 months 
for repeat assessment.















 (r=−0.51; p=0.013) at baseline. No 
statistically significant correlations were seen between 
FVC and DCE- MRI metrics. Follow- up at 6 months 
demonstrated statistically significant decline in FVC 
(p=0.040) and K
CO
 (p=0.014), with an increase in 
FWHM
mean






Conclusions DCE- MRI first pass perfusion 
demonstrates correlations with existing physiological gas 
exchange metrics, suggesting that capillary perfusion 
deficit (as well as impaired interstitial diffusion) may 
contribute to gas exchange limitation in IPF. FWHM
mean
 
showed a significant increase over a 6- month period and 
has potential as a quantitative biomarker of pulmonary 
vascular disease progression in IPF.
INTRODUCTION
Idiopathic pulmonary fibrosis (IPF) is the the 
most common idiopathic interstitial lung disease, 
carrying a natural median life expectancy of 2 to 5 
years from diagnosis,1 although recent advances in 
antifibrotic therapy may have somewhat improved 
the outlook.2 Most patients with IPF listed for lung 
transplantation exhibit elevated pulmonary arterial 
pressures, and many patients in the end stages of 
disease develop fulminant pulmonary hyperten-
sion.3 However, more than 60% of the capillary 
bed is lost before elevated pulmonary arterial pres-
sures are manifest at the time of right heart cathe-
terisation,4 the clinical gold standard of assessment. 
Recent data from quantitative CT assessment of 
blood vessel volume density suggests that loss of 
the small pulmonary vessels may be prognostic in 
IPF.5 Thus, a means of functionally assessing these 
changes may provide mechanistic insight into lung 
pathophysiology and a quantitative means of testing 
interventions targeted at treating the pulmonary 
vascular changes in IPF at an earlier stage.
Dynamic contrast- enhanced MRI (DCE- MRI) is 
clinically used for the functional assessment of perfu-
sion, predominantly in imaging the myocardium,6 
brain7 8 and oncological targets.9 10 Literature for 
imaging the pulmonary circulation with DCE- MRI 
in a clinical setting has to date largely focussed on 
pulmonary vascular disease,11 with other studies in 
disease such as cystic fibrosis and chronic obstruc-
tive pulmonary disease generally small and focussed 
on methodological development.12–14
DCE- MRI tracks the passage of a paramagnetic 
contrast agent bolus applied via a peripheral vein 
Key messages
What is the key question?
 ► Does dynamic contrast- enhanced MRI (DCE- 
MRI) provides a means of quantifying regional 
information of pulmonary perfusion in 
idiopathic pulmonary fibrosis (IPF)?
What is the bottom line?
 ► DCE- MRI first pass perfusion demonstrates 
correlations with existing physiological gas 
exchange metrics, shows increased pulmonary 
transit times in regions of fibrosis and 
progression over a 6- month time period.
Why read on?
 ► In light of recent trials failing to demonstrate 
efficacy of pulmonary vasodilator therapy in 
IPF, DCE- MRI may provide a novel means of 
phenotyping vascular changes and thus be used 
to enrich future study populations.






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































through the circulation in the organ of interest. In pulmonary 
imaging, the contrast can be visualised passing through the 
right atrium and ventricle, into the pulmonary arterial trunk, 
the pulmonary circulation, then into the left heart and systemic 
circulation. From the resultant time- resolved images, qualita-
tive inferences of cardiopulmonary vascular haemodynamic 
processes such as shunting and bronchial circulation can be 
observed. Moreover, quantitative metrics of regional blood flow, 
volume and transit time may be generated, allowing regional and 
global assessment of pulmonary perfusion to be made.
Pulmonary perfusion metrics have prognostic implications in 
patients with pulmonary arterial hypertension,11 but have under-
gone little exploration in interstitial lung disease (ILD). There 
may however be a role for gadolinium- enhanced MRI in the 
assessment of disease activity.15 Tsuchiya et al reported a rela-
tionship between reduced pulmonary blood flow measured using 
phase- contrast MRI and reduced lung volumes in 27 patients 
with ILD, but did not discover a relationship with lung physi-
ology, perhaps due to the heterogeneity of the lung diseases anal-
ysed.16 Other studies have identified that delayed or late phase 
contrast (images taken approximately 10 min after administra-
tion of intravenous gadolinium) mean signal intensity correlates 
with structural extent of fibrotic lung disease,17 and may even 
evaluate early fibrosis in patients with apparently morphologi-
cally normal lung.18
Herein, we present first pass perfusion DCE- MRI of the lungs 
as a means of assessing changes in blood flow through the lung 
parenchyma of patients with IPF.
METHODS
Study subjects
For this prospective, observational study, all participants 
provided informed written consent. The research was conducted 
according to the principles of the Declaration of Helsinki. Some 
participants in this study have been previously reported on in 
the context of hyperpolarised xenon MRI.19 However, none of 
the DCE perfusion MRI data in this article has been published 
elsewhere.
Twenty- three participants with a diagnosis of IPF were 
recruited through a tertiary interstitial lung disease centre. 
All diagnoses were clarified against international consensus 
criteria,1 in a multidisciplinary setting of respiratory physicians 
and thoracic radiologists. No lung biopsies were necessary in the 
diagnostic pathway. Participants had no evidence of pulmonary 
hypertension at baseline, from transthoracic echocardiography 
using the Bernoulli equation to assess estimated systolic pulmo-
nary artery pressure from tricuspid jet velocity as a standard 
method of clinical screening.20 Potential participants with stage 
4 or 5 chronic kidney disease were excluded prior to enrolment 
(n=2), due to the reported risk of gadolinium- induced nephro-
genic systemic fibrosis in the context of renal failure.21
Study design
Each of the 23 participants underwent a baseline DCE- MRI, 
between February 2016 and March 2019. Nineteen participants 
returned for repeat imaging at 6 months (mean 193 days; SD 17.7 
days). Four patients withdrew from the study prior to follow- up 
and subsequently died from respiratory failure. Pulmonary func-
tion tests were performed on the same day during both visits.
Imaging and physiology methods
Images were obtained on a 1.5T GE HDx scanner, with an 
8- channel thoracic array coil using a three- dimensional spoiled 
gradient echo time resolved view sharing sequence22 with 
parallel imaging.23 Pulse sequence parameters included: voxel 
size 2.4×6.0×10.0 mm3, bandwidth 250 kHz, flip angle 30°, TE 
1.1 ms, TR 2.5 ms, frame rate of 2 per s. The imaging temporal 
resolution ranged from: 0.597 to 0.826 s per whole lung volume 
(mean±SD = 0.664±0.051 s). Images were taken over 25 s at 
the end of tidal breathing following a bolus of  0. 05mL. kg-1 dose 
of Gadovist contrast agent (Bayer), injected through a peripher-
ally sited intravenous cannula at a rate of 4mL.s-1 with a 20 mL 
0.9% sodium chloride flush.
Pulmonary function tests included spirometry for forced vital 
capacity (FVC) and the single breath carbon monoxide assess-
ment of gas exchange in the seated position, providing transfer 
factor (T
LCO
) and coefficient (K
CO
) of the lungs. A 10 s single 
breath- hold manoeuvre was used as per international stan-
dards,24 repeated twice to ensure reproducibility.
Analysis
From the resultant MRI images, full width of half- maximum 
(FWHM) maps of the first pass of perfusion signal enhance-
ment were derived for each voxel within the lung parenchyma. 
Each voxel demonstrates an upslope in signal, until a peak signal 
enhancement is seen and a downslope as contrast exits the voxel. 
The FWHM (s) is taken as the time taken between the point 
where 50% of maximum signal intensity has been reached on 
the upslope and downslope as represented in the left panel of 
figure 1. The FWHM was averaged over the whole lung maps to 
give a mean value (FWHM
mean
) and the IQR (FWHM
IQR
) of the 
distribution of FWHM was used in order to provide a metric of 
perfusion heterogeneity.
The parametric maps of FWHM were generated for each 
participant,25 performed using custom- written code for 
MATLAB 2016a (The MathWorks, Inc., Natick, Massachusetts, 
USA), based on equation (2) from Lin et al.25 Each slice was 
manually segmented from the maximum intensity projection 
image using ITK- SNAP software.26 The left and right pulmonary 
veins, pulmonary artery and second generation pulmonary arte-
rial vessels were excluded from the segmentation. Voxels were 
only included in the FWHM calculation a point existed after the 
peak signal enhancement which was <50% of this peak value. 
Any voxels not analysable were set to zero and excluded from 
whole lung metrics reported.
All gas transfer metrics are studied in SI units, that is,  mmol. 
min-1.kPa-1 for TL
CO
, or  mmol. min-1.kPa-1.L-1 for K
CO
. Per cent 
predicted values for both FVC and TL
CO
 pertain to the Global 
Lung Initiative reference equations.27 28 Strength of correla-
tions between pulmonary function tests, and MRI metrics were 
assessed by Spearman’s rho. Wilcoxon signed- rank test evaluated 
the significance of 6- month changes in participants undergoing 
follow- up. P values stated are two- tailed. Statistical analysis was 
performed using GraphPad Prism 7 for Mac (GraphPad Soft-
ware, La Jolla, California, USA).
Post- hoc analyses between participants surviving versus not 
surviving to 6- month follow- up, as well as participants exceeding 
versus not exceeding the 95% upper limit of agreement of repro-
ducibility of FWHM
mean
 over 6 months were undertaken using 
Mann- Whitney U tests. No correction for multiple testing was 
performed.
RESULTS
All examinations were well tolerated, and no adverse events were 
reported. Baseline demographic, pulmonary function and DCE- 
MRI summary metrics are summarised in table 1. As described 














































































































above, any voxels not analysable were set to zero and excluded 
from whole lung metrics reported. This resulted in (mean±SD) 
80.5%±13.6% of voxels being included over the cohort. Details 
for each subject are available in the online supplemental material.
Reproducibility
During the first study visit, a cohort of six subjects underwent 
repeat DCE- MRI approximately 2 hours apart. Mean interscan 
bias in FWHM
mean
 was 0.35 s (95% CI −0.95to 1.66 s), while 
mean interscan bias in FWHM
IQR
 was 1.05 s (95% CI −3.62to 
5.74 s). Bland- Altman plots of repeatability can be found in the 
online supplement. An example quantitative parametric map of 
a subject undergoing imaging twice at baseline is provided in 
figure 2.
Correlation with baseline pulmonary function tests
No correlation was found between FVC and FWHM
mean
 
(r=−0.22; p=0.310; 95% CI −0.59 to 0.22), or FVC and 
FWHM
IQR
 (r=−0.14; p=0.529; 95% CI −0.53 to 0.30). 





 (r=−0.41; p=0.054; 95% 





p=0.026; 95% CI −0.74 to −0.05). K
CO
 showed mild- to- 
moderate correlations with both FWHM
mean
 (r=−0.42; 
p=0.047; 95% CI −0.71 to 0.01) and FWHM
IQR
 (r=−0.51; 
p=0.013 95% CI −0.77 to −0.11). There was a strong correla-





(r=0.77; p<0.001; 95% CI 0.52 to 0.90).
Change over 6 months







 over 6 months in the 19 patients followed up to 
6 months. FVC decreased by a median of 2.7% (p=0.040; esti-
mated 95% CI −6.0% to 1.02%). TL
CO
 decreased by a median 
of  0. 05mmol. min-1.kPa-1 (2.9%) (p=0.090; estimated 95% CI 
−4.86% to 1.02%). K
CO
 decreased by a median of 0.03  mmol. 
min-1.kPa-1.L-1 (p=0.014; estimated 95% CI −0.06 to 0.00 
mmol. min-1.kPa-1.L-1). FWHM
mean
 increased by a median of 
1.05 s (p=0.040; estimated 95% CI −0.65 to 3.14 s), whereas 
FWHM
IQR
 increased by a median of 0.09 s, but was not signifi-
cant (p=0.821; estimated 95% CI −1.87 to 0.95 s).
There were no statistically significant correlations between 





. There was a correlation between 
6- month change in FWHM
mean
 and 6- month change in FWHM
IQR
 
(r=0.55; p=0.015). All correlations are summarised in table 2.
Qualitative imaging analysis
The right panel of figure 1 shows the parametric maps of 
FWHM to demonstrate the spatial relationship between regions 
Figure 1 Left panel: Example of signal change through a parenchymal region of interest. The full width at half- maximum (FWHM) signal is often 
used as a standard threshold for integration. Right panel: CT with best matching coronal slice mean transit time (FWHM) maps derived from dynamic 
contrast- enhanced MRI from two participants (A+B and C+D). Reticulation and honeycombing on the CT is related to regions of increased transit time 
in basal and peripheral regions. Colour bar denotes FWHM in seconds.
Table 1 Participant characteristics and baseline data
Demographic Median IQR
Age (years) 69.5 65.7 to 71.6
   Sex 19 male; 4 female
   Height (cm) 171 169 to 178
Pulmonary function test
   FVC (% predicted) 83.1 70.9 to 95.7
   TL
CO
 (% predicted) 54.1 40.5 to 77.0
   K
CO
 (% predicted) 83.1 68.1 to 92.1
DCE- MRI metrics
   FWHM
mean
 (s) 8.01 7.01 to 8.88
   FWHM
IQR
 (s) 3.66 2.72 to 6.51
DCE- MRI, dynamic- contrast enhanced MRI; FVC, forced vital capacity; FWHM, full 
width at half maximum; FWHM
IQR
, IQR of the FWHM; FWHM
mean
, mean FWHM; K
CO
, 
diffusing coefficient of the lungs for carbon monoxide; TL
CO
, diffusing capacity of the 
lungs for carbon monoxide.














































































































of increased blood transit time and presence of fibrotic lung 
disease on the accompanying CT coronal image of the same 
participant. Figure 4 demonstrates progression of transit time 
across a 6- month time period in two participants.




Exploratory analyses were performed on those participants 
in whom the 6- month increase in FWHM
mean
 exceeded the 
upper limit of agreement on the Bland- Altman analysis (change 
>1.66 s) and those who did not meet this threshold (change 
≤1.66 s). Herein, these groups are referred to as progressors/
non- progressors, respectively, for clarity.
Baseline FWHM
mean
 (median difference −0.73 s; 95% CI 
−1.55 to 0.95 s) and baseline FVC (−2.22%; 95% CI −14.9 
to 20.8%), were lower in FWHM
mean
 progressors versus non- 
progressors. Baseline TL
CO
 (median difference 20.8%; 95% CI 
−16.6 to 34.4%) and change in TL
CO
 (median difference 4.4%; 
95% CI −5.15 to 5.73%) were higher in FWHM
mean
 progressors 
versus non- progressors. None of these differences were statisti-
cally significant.





 were compared in a post- hoc 
analysis between participants surviving to 6- month follow- up 





 were on average higher in the non- survivors (1.10 s 
and 1.29 s, respectively), although neither was statistically signif-
icant (p=0.218; 95% CI −0.77 to 3.71 and p=0.785; 95% CI 
−1.93 to 6.66, respectively). The small sample size in the non- 
survivor group should be noted.
DISCUSSION
The transit time of contrast through the lung increases in propor-
tion to worsening gas exchange in our IPF cohort and exhibits 
a mild strength of non- parametric correlation with established 
metrics of gas exchange, but not FVC. The FWHM
mean
 of the 
transit time demonstrates an increase in our sample IPF popula-
tion over a 6- month follow- up period and the IQR (FWHM
IQR
) 
may be a simple means of describing perfusion heterogeneity. 
Regional increases in transit time, although analysed on a purely 
qualitative basis in this study, appear to be spatially congruous 
with the known peripheral and basal distribution of disease in 
IPF.
Previous literature suggests changes in lung perfusion may 
represent loss of the vascular bed due to vascular remodelling.29 
Histologically, fibrotic regions contain epithelial cells under-
going apoptosis, but also proliferation,30 31 leading to a complex 
and aberrant vascular network involving anastomoses between 
alveolar capillaries and pulmonary veins. This disruption of 
perfusion contributes along with alveolar destruction and septal 
thickening to gas exchange impairment and thus explain the 




. Patients with 
IPF are at increased risk of venous and arterial clot formation,32 
leading to suggestions that intramural thrombus in the pulmo-
nary vasculature may also contribute to perfusion limitation in 
IPF.
Our model assumes that the FWHM
mean
 is a surrogate of transit 
time of blood through the lung and therefore can represent 
blood flow; with the FWHM
IQR
 a measure of heterogeneity.11 33 
IPF is generally thought of as a disease of the lung parenchyma, 
rather than a disease of perfusion limitation and while the paren-
chymal disease leading to diffusion limitation is the significant 
Figure 2 Reproducibility of regional full width at half maximum (FWHM). An example of one subject undergoing same day repeat imaging at two 
time points (A and B). Colour bar denotes FWHM in seconds.


















































































































 (B); FVC % predicted (C); K
CO





 % predicted (). Wilcoxon signed- rank p values quoted for each. FVC, forced vital capacity; FWHM, full width at half maximum; FWHM
IQR
, 




, diffusingcoefficient of the lungs for carbon monoxide; TL
CO
, diffusingcapacity of the lungs for carbon 
monoxide.














































































































mechanism that causes changes in TL
CO,
 the accompanying 
changes in capillary perfusion should also be considered in the 
understanding of gas exchange in IPF. If DCE- MRI can indeed 
identify subclinical changes in pulmonary perfusion, this tech-
nology may fulfil a clinical need to identify patients with early 
pulmonary vascular changes, disproportionate to the degree of 
ILD. Anecdotal observations of clinical improvement of some 
patients with IPF on sildenafil have been reported and there is 
biological plausibility of its effect,34 even though a randomised 
controlled trial of patients with IPF and low TL
CO
 demon-
strated no significant difference between subjects on sildenafil 
or placebo.35
Our findings differ somewhat from the findings of Tsuchiya et 
al, who used phase contrast MRI to evaluate blood flow within 
the pulmonary arteries.16 They found no relationship between 
pulmonary arterial flow and diffusing capacity, although severity 
quantified by CT was correlated with pulmonary arterial flow.16 
Their cohort was a wider population of patients with ILD, some 
of whom had IPF. Our population had a greater degree of diffu-
sion limitation (although the carbon monoxide gas diffusion 
coefficient, K
CO
 is not reported in their data) and a relatively 
better preserved FVC. Moreover, measurement of blood flow in 
the major pulmonary arteries is a global measurement of pulmo-
nary vascular resistance and while affected by the downstream 
changes in microvascular blood flow is not a direct measure of 
capillary perfusion.
Given that much of the capillary bed is lost before elevated 
pulmonary artery pressures are manifest, a sensitive means of 
detecting vascular changes earlier in the process may allow 
clinical trial stratification for those at risk of pulmonary hyper-
tension, or better inform lung transplantation decisions. Such 
markers may complement other MR sequences used in the 






r P value 95% CI r P value 95% CI
FVC −0.22 0.310 −0.59 to 0.22 −0.14 0.529 −0.53 to 0.30
TL
CO
−0.41 0.054 −0.71 to 0.02 −0.46 0.026* −0.74 to 0.05
K
CO





6- month change in FVC 0.02 0.949 −0.45 to 0.48 −0.34 0.154 −0.70 to 0.15
6- month change in TL
CO
0.16 0.537 −0.35 to 0.59 0.07 0.791 −0.43 to 0.53
6- month change in K
CO
−0.39 0.095 −0.72 to 0.07 −0.10 0.695 −0.54 to 0.39
* Designates p- value < 0.05
FVC, forced vital capacity; FWHM, full width at half maximum; FWHM
IQR
, IQR of the FWHM; FWHM
mean
, mean FWHM; K
CO
, diffusing coefficient of the lungs for carbon monoxide; 
TL
CO
, diffusing capacity of the lungs for carbon monoxide.
Figure 4 Representative parametric transit time (FWHM) maps from two participants each with baseline (A and C) and follow up (B and D) scans. 
Participant 12 (A and B) demonstrates an increase in FWHM in the right lower lobe and left mid- zone peripheral lung tissue. FWHM
mean
 decreased 
slightly by 0.13 s, with associated changes in FVC from 60.1% to 63.2%, and TL
CO
 from 37.1% to 33.0%, respectively. Participant 18 (C and D) shows 
a gross overall increase in FWHM, again worse in peripheral lung tissue. FWHM
mean
 increased by 4.35 s, in spite of both FVC and TL
CO
 remaining 
relatively stable from 76.0% to 74.5%, and from 87.2% to 88.2%, respectively. Colour bar denotes FWHM in seconds. FVC, forced vital capacity; 




, diffusingcapacity of the lungs for carbon monoxide.














































































































assessment of ILD. For example, ultrashort echo time MRI 
demonstrates improved structural image quality and resolution 
compared with conventional sequences and also provides a non- 
ionising alternative to CT and hyperpolarised xenon MRI has 
the potential to provide longitudinal,19 regional36 metrics of gas 
exchange.
The use of global measures is however, potentially problematic. 
It is possible that the increase in FWHM
mean
 over time is repre-
sentative of progression of another aspect of the disease process, 
rather than vascular injury. However, the participants with and 
apparently progressive FWMH
mean
 have a higher baseline TL
CO
 
and do not appear more likely to demonstrate progression in 
TL
CO
, nor FVC. Qualitatively, regions of increased FWHM
mean
 
appear analogous with regions of fibrotic disease on CT, though 
no quantitative analysis yet exists to support this. Therefore, 
assessment of the regional correlation of perfusion maps with 
129Xe maps of tissue and red blood cell uptake, alongside quanti-
tative regional assessment of CT is a logical next step in regional 
understanding of gas exchange using multimodal MRI.
The main limitation of this study is that it was conducted in 
a single- centre and in a relatively small number of participants. 
However, the statistically significant change seen in FWHM-
mean
 at 6 months demonstrates the potential of this approach 
for assessment of disease progression. Future work to provide 
description of more quantitative regional changes in other 
perfusion parameters may provide a means of detecting gradual 
progression. From a DCE methodological perspective, ongoing 
work with full quantitative perfusion analysis is being pursued 
in order to generate associated maps of regional blood flow and 
blood volume using T1 mapping and arterial input function 
deconvolution.37–39
Consideration should also be given to the role of anatomical 
positioning on perfusion. While TL
CO
 is typically measured in 
the sitting position, MRI is performed supine. This leads to a 
redistribution of flow from the usually dependant and optimally 
perfused basal lung tissue to the rest of the lung, which could 
affect transit times in the bases. However, one would still not 
expect transit times to be slower in the lung bases than the rest 
of the lung tissue in health in the supine position as is clearly the 
case in the example parametric maps provided. This makes the 
observed qualitative findings of increased basal and peripheral 
transit time much more likely to be disease related. As is visible 
in figure 2, there is greater repeated- measurement disagreement 
in the anterior slices. We propose this is likely due to the pres-
ence an anterior- posterior perfusion gradient, caused by blood 
pooling towards the posterior thorax under gravitational effect 
while the subject is in a supine position. This reduces the signal 
from the anterior slices and therefore reduces the signal to noise 
ratio. The anterior slices also contain a smaller volume of lung 
tissue, greater increasing the margin of error. The postural 
gradient and its associated impact on the findings should be 
considered in future studies.
The participants in our study did not undergo right heart 
catheterisation, the gold standard assessment for the presence of 
pulmonary hypertension. However, echocardiography is sensi-
tive in detecting the presence of pulmonary hypertension and is 
clinically used as a screening tool,40 and as such best represents 
the investigation that is routinely available in standard clinical 
practice.
Debate exists around the best technique by which to control 
for the effects of the respiratory cycle and thus intrathoracic 
pressure effects on pulmonary perfusion. Here, we have chosen 
end of tidal breathing to facilitate breath holding and reduce 
the risk of a Valsalva manoeuvre being performed. Respiratory 
gating may ensure functional residual volume is met, but is 
not available in many centres and regardless, the measurement 
of first pass enhancement requires the participant to perform 
a breath holding technique to mitigate for the effects of vari-
ation in intrathoracic pressures. Further methodological work 
on the optimal breath- hold technique may therefore be of value 
in future studies. Interscan reproducibility results may also be 
affected by slight alteration of the temporal resolution for each 
case. This was due to the bespoke slice positioning by the MR 
radiographer on each scan session. This as an experimental 
limitation that could be avoided with more stringent control 
of the slice positioning in future work. One possible solution 
would be to fix the slice coverage to ensure the same inter frame 
rate between all subjects. Further details of the temporal reso-
lution changes in the six participants who underwent same- day 
reproducibility imaging are presented in the online supplemental 
table. One significant consideration is the role of cardiac func-
tion in the quantitative metrics of our analysis. While patients 
with significant cardiac dysfunction were not recruited to this 
study, in clinical practice, the cardiac function of sexagenarian 
and septuagenarian population is likely to vary. This may in turn 
cause changes in global pulmonary flow metrics. Both systolic 
and diastolic dysfunction are commonly comorbid conditions in 
this age bracket and future studies may wish to consider including 
measures of systolic and diastolic cardiac function, either in the 
form of transthoracic echocardiography, or possibly in the same 
imaging sitting as the investigative endpoint with cardiac MRI. 
While the FWHM
mean
 appears relatively repeatable in our small 
cohort, the FWHM
IQR
 has a significant degree of variability, 
which may be problematic to its use as a clinical biomarker.
Overall, 80% of voxels returned an analysable result, but this 
leaves a not insignificant amount of the lung tissue that could 
not be analysed. The overall reduced perfusion in the IPF lung 
may induce underestimation bias of the transit time, particularly 
in the most severely affected disease. Future work on developing 
the methodology of this approach therefore needs to account 
for this.
The potential effects of antifibrotic therapy are not accounted 
for in this study, and some participants commenced antifi-
brotic therapeutics after the initial baseline study visit, which 
may therefore affect follow- up results. However, none of these 
participants were taking pulmonary vasodilator therapy and 
none were part of the recently reported trial of nintedanib/silde-
nafil versus nintedanib/placebo.35
In conclusion, DCE lung perfusion MRI is feasible and well- 
tolerated in a population of participants with IPF. Of the two 
candidate markers described here, FWHM
mean
 appears to be 
more reproducible than FWHM
IQR
. Although there is a paucity 
of data to determine reliably whether the mean interscan bias 
of 0.35 s is significant, it appears lower than the mean 6- month 
change of 1.05 s. Whole lung metrics of transit time correlate to 





significantly increases over a 6- month time interval. The regional 
information contained within the parametric maps may provide 
a novel means of assessing early perfusion changes in this popu-
lation in the absence of detectable pulmonary hypertension on 
echocardiography and future research in this area could focus 
on quantifying these changes on a regional basis to enhance the 
sensitivity of this technique for use in early intervention trials.
Twitter Stephen Renshaw @steverenshaw
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Temporal resolution was altered slightly for each case due to the bespoke slice positioning by the MR 
radiographer on each scan session, we acknowledge this as a potential limitation and this has now 
been included in the discussion of the manuscript. This is reported in the table below. 
 
Patient Session A  
temporal resolution 
Session B  
temporal resolution %difference 
IPF01 0.643 0.598 -7.00% 
IPF05 0.643 0.605 -5.91% 
IPF06 0.735 0.689 -6.26% 
IPF08 0.643 0.605 -5.91% 
IPF12 0.689 0.689 0.00% 
IPF13 0.643 0.605 -5.91% 
 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) Thorax
 doi: 10.1136/thoraxjnl-2019-214375–8.:10 2020;Thorax, et al. Weatherley ND
These data tables describe the standard deviation of FWHM per slice for every subject 
IPF01_V1 IPF01_V2 IPF01_V3 IPF02_V1 IPF03_V2 IPF03_V3 IPF04_V1
0 0 0 0 0 0 1.375824039
0 0 0 0 0 3.748868363 1.125908851
3.230170062 1.906742047 0 0 0 1.632178465 1.365361449
1.145578372 1.075037303 1.857315571 3.688019809 1.303071621 0.982666973 1.321468181
1.286840013 1.430626114 1.699289184 1.953734127 1.827663589 1.12096587 1.408456014
1.352593464 1.530760124 1.660268208 1.335187306 1.690528544 1.218392555 1.480310123
1.403170747 1.683851347 1.38756886 1.476129077 1.326370021 1.362138037 1.722864528
1.393082117 1.657934782 1.494826372 1.420648213 1.923430187 1.63828986 1.99141668
1.626379469 1.782973958 1.625285116 1.513076618 1.790750775 1.943733661 2.266157421
1.920743309 1.784817782 1.786582751 1.820972211 2.49580359 2.329845476 2.101947784
1.872853293 1.880359735 1.76293266 1.845032521 2.811838743 2.327241407 2.105683184
2.233703356 1.923056052 2.046335492 1.479539121 2.918170339 2.493145778 2.339599502
2.506628053 2.078024561 2.16986447 1.675524796 2.960871929 2.927609646 2.727234442
2.617540073 2.463001677 2.105974531 1.781407648 3.323558941 2.940833567 2.596737392
2.458995992 2.933867039 2.29903174 1.857108076 3.143460355 3.095392584 1.978425245
2.30636281 2.728440877 2.502830321 1.955440327 3.25598213 2.957795196 2.506315762
2.552244481 2.991197164 2.31851815 1.763647945 3.446258895 3.204356843 2.78440554
2.625109073 3.225569955 2.40683953 1.759452721 3.213986197 3.518511989 3.34212727
3.020090034 3.943758462 3.033351668 4.230249116 3.667680958 3.575192711 4.405564108
3.154947993 3.580125078 3.47653254 1.231200962 4.023852445 3.753483134 3.33901327
3.908026867 3.534013891 3.818088689 0 4.743311539 4.611754829 5.188491602
0 0 2.814635452 0 4.649302606 4.837745364 7.219525561
0 0 0 0 5.060903593 4.878497705 0
0 0 0 0 5.625570606 4.220317869 0
0 0 0 0 5.975555691 3.215654658 0
0 0 0 0 6.462019654 0 0
0 0 0 0 8.068960758 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
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IPF04_V2 IPF04_V3 IPF05_V1 IPF05_V2 IPF06_V1 IPF06_V2 IPF06_V3
0 0 0 0 0 0 0
2.101566926 2.407905315 2.628085102 0 0 0 4.779499874
1.782033568 1.17143759 1.635086512 0 0 2.355386149 2.75115271
1.431983214 1.230290405 1.11021529 0 1.183858123 1.901782355 3.434184354
1.430324119 1.272896664 1.142469335 1.562522059 2.016176795 2.567791826 3.31498729
1.427876968 1.323878003 1.160410704 1.448325365 2.09412143 2.353439783 2.657851682
1.363144576 1.313493919 1.254562393 1.48473594 1.57976901 2.253247083 2.503339397
1.557154344 1.414194174 1.499161617 1.348770618 1.977673861 2.574079414 2.912128229
1.694757555 1.343505103 1.863061537 1.618377431 1.96930177 2.308093665 2.469821736
1.847340889 1.562230279 2.021554367 1.594925108 2.832096139 2.461667291 3.282761729
1.84529581 1.662900671 2.431931699 2.059732315 2.969284677 2.640523067 2.723555356
2.304994342 1.701625204 1.819948892 2.128989014 3.276411133 2.6200721 2.074377965
2.248092968 1.6794586 2.053218753 1.980898864 3.248154173 2.749234933 2.646756436
2.240958749 2.041633342 1.906578204 1.820173291 3.405745093 2.779688463 2.361797019
2.325758126 1.893964968 1.823289982 2.118689015 3.368634103 3.01635492 2.719623814
2.761169126 1.797790922 1.939750377 1.766482109 3.082164499 2.841203427 3.285824487
2.789763509 1.402569768 1.805650033 1.836427986 2.885924297 2.923225691 2.599963448
2.9575712 2.278651664 1.527566317 1.826385896 2.381152434 2.53235805 2.531148951
3.221988244 3.676087249 1.810094149 2.296160783 2.476330003 2.658745237 2.272354196
3.985506421 2.462135033 1.649431344 2.090344719 2.889261848 2.443728539 1.816584702
3.946584542 2.580316983 1.046589216 2.221877768 3.196297812 2.131087193 1.499441447
3.964395283 3.165881754 0 1.880610545 2.730593753 2.358672115 1.592662187
6.104966719 0 0 1.656334254 3.12871259 2.53082418 0
0 0 0 0 2.862726276 2.973090537 0
0 0 0 0 4.724100032 0.990286317 0
0 0 0 0 4.526939886 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
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IPF08_V1 IPF08_V2 IPF08_V3 IPF09_V1 IPF09_V2 IPF09_V3 IPF11_V1
0 0 0 0 0 0 0
1.828870216 0 0 0 0 0 0
1.077034966 0 0.959237954 0 0 0 0
1.153258075 4.680802125 1.298837609 0 0 0.843128374 0
1.235539071 1.347535942 1.436757022 4.098781282 2.028452705 2.105108959 1.461226594
1.318385668 1.431561114 1.364820837 3.818596022 1.354007069 2.732747072 3.976560455
1.413360181 1.610812956 1.302217393 3.195348067 1.765147521 3.321821548 3.374685682
1.396500587 1.618065482 1.518047237 2.34264092 1.712217326 1.811825774 3.357033383
1.525815032 1.679591479 1.487386881 2.190767911 2.356626246 2.549355901 2.626342542
1.594114359 1.732340185 1.380395088 2.075551402 2.528236697 2.591571128 3.237675855
1.898281169 1.81898952 1.457200681 2.554312521 2.596622584 3.188405242 3.300479139
2.221091083 1.978872926 1.588209965 3.426790901 2.734072407 3.018749414 3.502643647
2.190837686 2.059816868 1.748222145 3.471838564 3.055851907 4.565253725 2.949412859
2.001888353 2.203944989 1.822300786 3.582833088 3.970822297 3.465685539 3.018828849
2.226961813 2.165827768 1.884625042 3.7095501 3.881410929 4.589568644 3.581447884
2.55229556 2.092107783 1.520290813 3.890760865 4.842065088 5.437635225 3.976263913
2.566831142 1.806397484 1.855170552 4.493674826 5.777018942 6.632423062 4.083508064
2.698540007 2.265078738 2.009294786 4.738559775 6.989479836 6.824658095 3.554035975
3.495081001 2.31835426 2.635832269 3.771460861 6.173405545 6.208368653 3.524215495
3.194110061 3.070154075 2.546697159 4.066856528 5.72028172 4.846190897 3.428499116
3.453764313 2.482746983 2.662195916 5.19020279 5.912863386 6.429776051 3.664323637
0 3.25804192 3.437701921 0 0 2.407647251 0
0 2.566285376 0 0 0 0 0
0 2.210053913 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
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IPF12_V1 IPF12_V2 IPF12_V3 IPF13_V1 IPF13_V2 IPF17_V1 IPF17_V2
0 0 0 0 0 0 0
0 2.074204391 0 1.255748091 0 1.199959673 2.76809503
2.110561266 1.212538364 0 4.030969904 1.021286229 1.145512679 1.057263087
3.016784115 1.699389662 0 3.510784247 4.085198181 1.210771566 1.113948636
3.162909335 1.591383077 0 2.611615356 4.707111646 1.00039061 1.100251693
2.593645694 1.556866968 0 3.098426355 4.315379843 1.084243207 1.228128872
2.082812641 1.623359367 2.454492682 2.738677859 3.548676646 1.061083589 1.211914864
2.262360798 1.814524065 2.530261652 3.448884884 3.471403679 0.973416722 1.076818177
2.419571602 1.897621935 2.03809788 3.654586163 4.028213235 1.20603622 1.303643259
3.052123335 2.380764423 2.114754698 3.974291356 4.317561287 1.296374961 1.515199687
2.799923146 2.833539354 2.257399142 3.988111493 4.274501263 1.336740613 1.461945062
3.132079161 2.44288981 2.710164181 4.115754873 5.064336787 1.395754089 1.782012756
2.913582958 2.663130577 2.974716836 4.727030231 5.202548189 1.398256345 1.844263852
3.179501945 2.408825171 3.285418206 5.048028077 5.417516035 1.841918678 2.27272072
3.062697718 2.479424954 3.393019754 4.922607189 4.823458746 1.776236373 2.171742137
2.51548944 2.338881858 3.272415071 5.264795265 5.067293871 1.741791948 2.440322323
2.648677373 2.068851678 3.884072611 5.131259214 5.028888415 1.894160563 2.315774561
2.603112211 1.960689682 3.4274487 5.392243964 5.05176042 2.388187188 3.323349863
2.165664567 2.365727965 4.054362795 5.319592233 5.526683335 2.468171475 3.440314631
2.001829965 1.654841652 4.204053682 5.414025353 5.186883374 2.330023686 5.252942521
1.878244052 2.016519399 3.490970637 5.699328729 4.99010428 1.099750894 1.57643385
2.10200195 1.099687585 3.780117163 0 3.790874596 0 0
1.600629449 0 2.40966641 0 0 0 0
1.316105325 0 1.716362845 0 0 0 0
0 0 1.48073427 0 0 0 0
0 0 1.669868274 0 0 0 0
0 0 1.312735103 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
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IPF17_V3 IPF18_V1 IPF18_V2 IPF18_V3 IPF19_V1 IPF19_V2 IPF19_V3
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 1.168610606 0 0 3.830906253 0 0
0 1.253271798 0 0 1.658885603 0 0
2.827951864 1.22524803 0 0 1.564558966 3.427635666 0
1.540879479 1.165875174 5.521600518 1.291000438 1.599392274 2.448697863 2.262754241
1.317347122 1.305487753 2.37133853 1.834717644 1.710520383 1.972744608 2.302455923
1.225564359 1.263676396 1.634827777 1.825278478 1.907156693 2.347054148 1.794889349
1.099896005 1.336268473 1.695441994 1.89559919 1.736656319 2.475332354 2.062546873
1.143975222 1.559081387 1.861157939 1.896594564 1.68283542 1.617638798 2.089313554
1.294239124 1.857975853 1.720092043 2.104644541 1.935420024 1.906055835 1.886934367
1.600326698 1.536751799 2.145570607 1.856086886 1.852680257 1.793993207 1.763664594
1.595989388 1.844359813 2.19294275 1.961431522 1.815691187 1.279580362 1.700371218
2.070467497 1.843559716 2.221273791 1.77225189 1.705742585 1.375410195 1.661324903
2.280367536 1.848020996 1.870622822 2.247952447 1.623894598 1.299992194 1.725069162
2.355326691 1.983830084 1.883358252 2.198620871 1.957229925 1.352907403 1.50471312
2.538635529 1.905689724 1.867367572 2.002523845 2.370540685 1.452686703 1.683980396
2.469781661 1.897271891 2.509383509 2.064261519 2.797826674 2.267597671 1.742451138
3.006016389 1.811402319 2.219405663 1.875472149 2.211413466 1.337887695 1.591065264
2.763742409 2.885260003 2.068896428 1.881679886 2.555572541 1.173954939 1.871962905
2.469640695 3.39218774 1.583092122 1.838542756 3.891036629 0.836633064 1.740272167
3.247139695 0 2.623203659 2.144085861 4.364970996 0.925709352 1.361008852
4.322293544 0 3.587435477 2.61874684 1.553939781 2.501978666 0.953218298
5.467068142 0 3.422099245 2.178282681 0 3.409983086 1.585430129
6.548063056 0 0 0 0 0 1.566342114
0 0 0 0 0 0 0
0 0 0 0 0 0 0
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IPF22_V1 IPF22_V2 IPF22_V3 IPF23_V2 IPF23_V3 IPF24_V2 IPF24_V3
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 1.336801467 0
0 1.087381147 1.687066922 0 4.06932642 1.503086385 1.427708191
0 1.130399758 2.01377952 4.105579905 5.053256724 1.441359483 2.067733798
1.650577661 1.117370705 2.550286015 2.846929962 2.986608506 1.457078352 1.867418926
1.535318112 1.015306536 2.744535756 2.068308661 3.0043902 1.631137352 1.660149233
1.523295779 1.027376517 2.721351961 1.990930618 3.189237434 1.467152719 1.782029823
1.386451123 1.160961461 2.97796632 2.265211095 3.857465824 1.642659063 1.646202971
1.340596314 1.210789905 3.05959834 2.311393843 3.81546745 1.706212058 1.89685748
1.344348595 1.20744384 2.731819862 2.370188619 3.884386194 1.459537075 1.99360069
1.613061159 1.306225622 2.962876896 2.969291348 4.113009333 1.685981036 2.209436173
1.746284341 1.345880072 3.384361172 3.763301873 4.572954909 2.452038799 2.006652338
1.78058704 1.378041141 3.791709446 4.030662297 4.601103918 2.806133844 1.918580403
2.114208414 1.232340722 3.709675336 3.389808487 4.428143152 2.809721351 3.561880361
2.115570421 1.132295699 3.662799103 2.782098018 4.623369412 2.295863564 2.23316157
1.722378666 1.400411199 3.70205631 2.387044814 2.631926841 1.91653083 2.169282396
1.851614191 1.436080998 3.985785408 3.040494576 1.154489567 2.512372569 2.121826106
1.775924692 1.566191988 4.995248303 2.809103251 0 2.103579498 2.260077567
1.777531678 1.811537547 4.404215848 0 0 3.556470426 2.316689963
1.88475686 2.415198832 3.505431147 0 0 4.947412467 2.653906724
2.13828084 0 0 0 0 0 2.592518203
1.957888441 0 0 0 0 0 2.230205079
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
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IPF24_v1 IPF25_V1 IPF25_V3 IPF25_v2 IPF27_V1 IPF27_V2 IPF27_V3
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0.824843471 0 0 0 0 0 0
0.939678242 0 0 3.754684962 0 0 0
0.997406991 1.752369665 3.044465244 3.281850071 1.193342203 2.063722046 1.573324069
0.983112297 1.748559785 2.672557288 2.794306057 1.22045329 1.717466215 1.018325241
1.071859149 1.490649811 2.3049345 2.776145587 0.997880641 1.262116641 1.154242635
1.090940616 1.588479608 2.311856315 2.930443489 1.171312312 1.26696551 1.327358899
0.966090215 1.779758782 2.680946444 2.832509657 1.188206582 1.582781063 1.499906718
1.099548093 2.110943443 2.988459749 2.687127312 1.660239032 1.788779701 1.737437215
1.264074262 2.271194886 2.957232872 2.924808565 1.644010543 1.978146742 1.713989194
1.365526634 2.140826613 3.023175723 2.786433652 2.074694689 1.526931135 1.730266658
1.219402875 2.158794037 2.880166834 2.771650753 1.807032706 1.490339139 2.000324652
1.312166519 2.075952285 2.757915424 2.712842479 2.120445557 2.07722687 2.086843418
1.133506395 1.853062994 2.807001982 2.747339838 2.044426821 2.217037174 2.151193598
1.308444936 1.760171293 2.616081684 2.546313019 1.971594965 1.835469421 1.855977987
2.1451825 1.653417222 2.499428079 2.28261294 2.127432213 2.26393605 2.077739021
1.521353513 1.549364146 1.97841875 1.808360246 1.930723094 2.427283824 2.459975071
1.721243911 1.903289862 2.35319478 2.523192611 2.336026005 2.138106081 1.958475243
1.937688354 3.184088034 3.119830484 2.974330163 4.326199389 2.748393124 2.692704833
1.489151782 2.03173371 4.478564171 0 0 2.659243572 4.030218952
0 0 0 0 0 0 0
0 0 0 0 0 0 0
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IPF28_V1 IPF28_V2 IPF28_V3 IPF29_V1 IPF30_V1 IPF30_V2 IPF30_V3
0 0 0 0 0 0 0
0 0 0 0 0 0.72846992 0
0 1.153166537 0 0 1.176987686 1.062423994 5.107704931
1.084125937 1.855362231 0 1.059102435 0.897933086 1.066668575 1.601931377
0.948280361 1.458996856 0 1.217159576 0.950141683 1.506374576 1.381382788
1.162354508 1.209450859 0 1.011179099 1.18690558 1.388796961 1.508622272
1.06432752 1.441018856 0 0.854324949 1.162585616 1.567699756 1.681343217
1.141669217 1.770136644 1.308746588 0.841839591 1.202732628 2.006899654 1.67158644
1.196513612 1.595228045 1.166246385 0.878972127 1.564387619 1.719297771 1.657281436
1.015497086 1.948235466 1.400162864 1.304654206 1.221552505 1.993370274 1.781162791
1.262350444 2.583749915 1.281499993 1.445297112 1.497253522 2.094106701 1.570765163
1.13419116 2.641607981 1.590225146 1.472766988 1.844680054 1.777879446 1.745450348
1.373379347 2.015810937 1.839559608 1.390682864 2.497596587 2.119881719 2.15964343
1.450860375 2.406739355 1.592742356 1.716056446 1.793868846 2.36340811 1.783323662
1.445820976 2.218554415 2.417340769 1.627747967 1.76160225 1.957871572 1.772831572
1.391731511 3.368688055 2.191427492 1.577439156 1.751728368 1.953970682 1.944007854
1.5627032 2.736484498 3.11569885 1.301153522 1.248501064 1.874267179 1.760911693
2.389165515 2.501169476 3.14721484 1.578490633 1.432332045 2.129800724 1.627252821
2.453654718 0 2.212975309 0 1.423588659 1.563237639 1.578856472
0 0 2.726457502 0 1.192093147 2.124714838 1.534852137
0 0 2.1619833 0 1.327310903 0 1.398440425
0 0 3.288141594 0 1.60645129 0 1.700486315
0 0 3.482793813 0 0 0 1.632826124
0 0 0 0 0 0 0
0 0 0 0 0 0 0
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IPF31_V1 IPF31_V2 IPF31_V3 IPF32_V1 IPF32_V2 IPF33_V1 IPF34_V1
0 0 0 0 0 0 0
0 0 0 0 0 0 0
1.64763968 2.197271472 0 0 0 0 0
1.309145237 1.956502769 2.021411016 0 3.128768613 2.99499872 1.338697174
1.910340284 2.0943918 1.778558213 4.362967021 3.049790923 3.269441444 1.372901289
1.958932696 1.956475441 1.730799689 2.814663716 3.013375979 2.938405375 1.707095569
1.713382665 2.111867644 1.765584437 2.456831671 2.772328654 3.339852839 1.679097375
1.640386312 1.957302848 1.876921803 2.772539692 3.257826572 3.179242352 2.108763456
1.976149099 2.125957714 1.495779757 3.286845917 3.652636994 3.1194374 2.435653968
1.766130431 2.119775824 2.082515436 3.135664504 3.510928152 2.619240859 2.137622492
2.629913364 1.736042029 1.669154386 3.029542625 3.700587245 2.478013139 2.507360387
2.008307989 1.900226475 2.101669556 3.749262893 3.575116173 2.355089636 2.655270789
1.880264437 1.90555339 2.139954931 3.748620514 3.812548089 2.71286603 2.419463008
1.898459637 2.015758004 2.092596734 4.693787542 3.717474996 2.783263179 2.569656535
1.790200237 3.12299288 2.389676333 4.603670379 3.567710421 2.794329669 2.396426858
1.935884728 3.031534318 2.569417155 4.475660497 3.529608739 2.433705526 2.061387046
2.169068178 2.8327809 2.327800107 3.630997433 3.677359059 2.735207037 2.212752707
2.302962996 3.289866321 2.942415445 2.917842335 2.784378179 2.905826511 2.539450191
2.684733757 3.805968621 3.347128935 3.771501618 2.279443122 3.291742624 2.879769755
0 6.115373689 5.854168741 3.25219041 2.113995188 2.90096216 3.091689254
0 0 0 3.351196531 0 0 3.419425569
0 0 0 1.639801512 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
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